Henry Ginsberg, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1356406268
Payments from drug & device makers
Across 130 payments — averaging $7767.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$420K
- Amgen$224K
- Pfizer$214K
- Merck$61K
- Kowa Research Institute, Inc.$52K
- Ionis Pharmaceuticals, Inc.$15K
- plus $24K from 16 others
Across 7 payments — averaging $1471.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$9K
- Sanofi-aventis U.S. LLC$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $419,975 |
| Amgen | 20 | $223,854 |
| Pfizer | 3 | $214,078 |
| Merck | 53 | $60,958 |
| Kowa Research Institute, Inc. | 14 | $51,574 |
| Ionis Pharmaceuticals, Inc. | 14 | $15,038 |
| Boehringer Ingelheim International GmbH | 1 | $3,716 |
| Astrazeneca AB | 1 | $3,600 |
| Sanofi-aventis U.S. LLC | 1 | $3,490 |
| Janssen Research & Development, LLC | 1 | $3,000 |
| Regeneron | 1 | $2,140 |
| Intercept Pharmaceuticals, Inc. | 1 | $2,100 |
| Novo Nordisk | 4 | $1,409 |
| Mirum Pharmaceuticals, Inc. | 1 | $1,300 |
| Astrazeneca UK Limited | 1 | $1,074 |
| KOWA Company, LTD. | 1 | $1,000 |
| Novo Nordisk AS | 1 | $850 |
| Novartis | 3 | $184 |
| BETA Bionics, Inc. | 2 | $158 |
| Kowa Pharmaceuticals America, Inc. | 2 | $146 |
| Esperion Therapeutics, Inc. | 1 | $118 |
| Eli Lilly | 1 | $65 |
How this compares
$1,009,828 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
- Elizabeth ShaneNew York$458K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.